Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 15/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.62 |
| ▸ | KDM1A | O60341 | 4/20 | 0.54 |
| ▸ | MAOA | P21397 | 4/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5851617 | 0.89 | P2RY12 (0.82) | P2RY12MEN1KMT2AKDM1AMAOA | |
| SCHEMBL16090494 | 0.89 | P2RY12 (0.63) | P2RY12MEN1KMT2AKDM1AMAOA | |
| SCHEMBL16090497 | 0.88 | P2RY12 (0.62) | P2RY12MEN1KMT2AKDM1AMAOA | |
| SCHEMBL19032302 | 0.86 | MEN1 (0.60) | P2RY12MEN1KMT2A | |
| SCHEMBL5849851 | 0.86 | P2RY12 (0.77) | P2RY12MEN1KMT2AKDM1AMAOA | |
| SCHEMBL5849479 | 0.85 | P2RY12 (0.62) | P2RY12MEN1KMT2A | |
| SCHEMBL19049676 | 0.85 | P2RY12 (0.73) | P2RY12MEN1KMT2A | |
| SCHEMBL7060963 | 0.85 | MEN1 (0.78) | P2RY12MEN1KMT2A | |
| SCHEMBL16090495 | 0.84 | MEN1 (0.58) | P2RY12MEN1KMT2AKDM1AMAOA | |
| SCHEMBL16090496 | 0.84 | P2RY12 (0.64) | P2RY12MEN1KMT2AKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | P2RY12 111/4885MEN1 2603/4885KMT2A 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.